CSIMEMPHIS: Long-term Follow-up of Medulloblastoma Survivors That Received Craniospinal Irradiation

The study is being done to learn more about the long-term health and well-being of participants treated for medulloblastoma. The study is to decide which evaluations focusing on therapy-related lasting effects (or toxicities) should be considered. Medulloblastoma outcomes have improved with contemporary therapies including modern neurosurgical techniques and risk-adapted radiotherapy and chemotherapy regimens. However, survivors remain at risk for long-term health problems such as neurocognitive deficits, hearing loss, impaired cardiorespiratory fitness and physical performance, cardiac and neuroendocrine dysfunction, musculoskeletal conditions, and infertility.

NCT Number	NCT07085325
Lead Sponsor	St. Jude Children's Research Hospital
Conditions	Medulloblastoma
Enrollment	184 participants
Start Date	2026-04-20
Primary Completion	2030-10 (estimated)
Study Completion	2031-10 (estimated)
Updated on ClinicalTrials.gov	2026-07-06